SOURCE: AMI Research

AMI Research

April 28, 2011 15:49 ET

AMI Research Updates Analyst Coverage on NeoGenomics; Maintains Outlook

NEW YORK, NY--(Marketwire - Apr 28, 2011) - AMI Research, ( a leading provider of equity research reports and a division of IR Firm, Hawk Associates Inc., announced today that it has published updated equity research coverage on NeoGenomics, Inc. (OTCBB: NGNM) based on its first quarter 2011 financial earnings results.

AMI president Peter J. D'Agostino said, "NeoGenomics reported results that were in line with our expectations. The company has been able to successfully manage costs and has begun to benefit from the new sales and marketing initiatives that it put in place last year. We expect NGNM to return to quarterly profitability in the fourth quarter with the help of a strong pipeline and a focus on new business development."

AMI Research provides an institutional-quality, equity research report detailing NeoGenomics' first quarter. The comprehensive report analyzes NGNM's key statistics, management, growth catalysts, financial outlook and valuation. The complete 8-page report is available to download for free at the AMI Research website,

About NeoGenomics
NeoGenomics Inc., ( is a CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. Staffed with specially trained hematopathologists and cytogenetic professionals, NeoGenomics Laboratories offers testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics through its network of regional laboratories. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit

About AMI Research
AMI Research is a wholly owned subsidiary of Hawk Associates and provides fundamental business analysis for promising companies that do not have traditional Wall Street analyst coverage. AMI Research creates comprehensive and quality equity research reports for small cap and microcap companies that need to reach investors. These detailed reports provide retail, individual and institutional investors with an in-depth understanding of a company's intrinsic value and its technology. The AMI equity research reports detail the company's industry, strategic position, core business model, financial history and future growth catalysts. Please visit

AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). The cost of a one-year continuing research program is $30,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst's compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report.

For more information, contact Peter J. D'Agostino, president at 212.541.2465, email to: or visit

Contact Information